Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

Participants who are clinically scheduled to undergo F-18 FDG PET/CT myeloma evaluation will
also undergo F-18 FDG PET/MRI, and C-11 acetate PET CT/MRI. On Day 1 of study, participants
will undergo F-18 FDG PET/CT-MRI. F-18 FDG radiopharmaceutical is infused intravenously,
followed by a 60 minute waiting uptake phase. After 60 minutes, participant will undergo
PET/CT imaging for 30 minutes. At 90 minutes, participant will undergo PET/MRI imaging for 30
minutes. On Day 2 of study, participants will undergo C-11 PET/CT-MRI. C-11
radiopharmaceutical is infused intravenously, followed by a 10 minute uptake phase. After 10
minutes, participant will undergo PET/CT imaging for 30 minutes, followed by a 60 minute
pause with the participant at rest. At the end of 60 minute pause, the participant is given
the second C-11 acetate infusion, followed by a 10 minute waiting uptake phase. After 10
minutes, participant will undergo PET/MRI imaging for 30 minutes. On Day 3, study team member
makes a phone call to participant for follow up.

Inclusion Criteria:

- Patients being staged for multiple myeloma as follows: new diagnosis, high risk
smoldering multiple myeloma, relapsed as defined by investigator

- Patients who have undergone standard of care workup

- 300 pounds or less

- Can provide informed consent

- Scheduled for a clinically indicated F-18 FDG PET scan

- English speaking

Exclusion Criteria:

- Pregnant, breast feeding

- Concurrent active non-multiple myeloma malignancy

- Contraindication to PET MRI

- Previous Type I or Type II Diabetes mellitus or a fasting blood glucose >150 mg/dl